Thermo Electron/Puritan-Bennett
This article was originally published in The Gray Sheet
Executive Summary
Waltham, Massachusetts-based Thermo extends until midnight on Dec. 8 its $24.50-per-share cash tender offer for outstanding common P-B shares. Thermo made the offer on Oct. 25 and has since extended it twice. Thermo says that this extension is "in light of the substantial support the offer has received from shareholders so far," as well as "new shareholder litigation filed in Delaware seeking to invalidate certain anti-takeover measures applicable to our offer." Respiratory products manufacturer P-B has urged its shareholders to reject the tender offer, saying it is inadequate. As of Nov. 28 -- the offer's most recent expiration date -- about 8.4 mil. shares had been tendered, representing approximately 72% of all outstanding P-B common stock and 67% on a fully diluted basis
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.